Ligands that bind to the allosteric-binding sites on muscarinic acetylcholine receptors alter the conformation of the classical-binding sites of these receptors and either diminish or increase their affinity for muscarinic agonists and classical antagonists. It is not known whether the resulting conformational change also affects the interaction between the receptors and the G proteins. We classical-binding site (12-18). The attachment of the allosteric modulator to the allosteric-binding site brings about a change in the conformation of the classical (orthosteric)-binding site and thereby an increase or (more usually) a decrease in the affinity of the receptor for muscarinic agonists and competitive antagonists.
classical-binding site (12) (13) (14) (15) (16) (17) (18) . The attachment of the allosteric modulator to the allosteric-binding site brings about a change in the conformation of the classical (orthosteric)-binding site and thereby an increase or (more usually) a decrease in the affinity of the receptor for muscarinic agonists and competitive antagonists.
The effects of the activation of the allosteric-binding site on the function of the classical-binding site (as reflected by changes in the association, dissociation, and equilibrium binding of muscarinic agonists and competitive antagonists) have been amply investigated (6) (7) (8) . However, little attention has been paid to the possibility that the allosteric modulators might also affect the conformation and function of the G protein binding site and, consequently, the interaction between muscarinic receptors, G proteins, and the G protein-regulated effector molecules. We present evidence that the allosteric modulators alcuronium, gallamine, and strychnine acting in the absence of agonists have profound agonist-like effects on the synthesis of cAMP and inositol phosphates (IPs) in cells stably transfected with the genes for muscarinic receptors and that, apparently, muscarinic receptors can be activated not only by ligands acting via their classical-binding site, but also by ligands acting via the allosteric-binding site. We suggest that the same novel mechanism of receptor activation may operate on the other G protein-coupled receptors.
Muscarinic acetylcholine receptors belong to the large group of receptors coupled with G proteins (1) . Signal transduction from the M2 and M4 muscarinic receptor subtypes occurs preferentially via the guanine nucleotide-binding regulatory proteins Gi and Go, whereas the M1, M3, and M5 receptor subtypes couple preferentially with proteins of the Gq family (2, 3) . Muscarinic agonists bind to the classical-binding site, which is located in the depth of the cell membrane in a barrel formed by the seven transmembrane segments of the receptor molecule (4, 5) . Agonist binding brings about a change in the conformation of the intracellular receptor domain responsible for the contact with the G protein, and this change brings about the activation of the G protein. Although details of these interactions are the subject of scrutiny and debate, it is generally believed that the attachment of the signal molecule to the classical-binding site is the necessary first step in muscarinic receptor-mediated signal transduction across the cell membrane.
However, it is well known that the binding properties of the classical-binding sites of muscarinic receptors are subject to allosteric regulation by modulators that associate with one or more allosteric-binding site(s) on the receptors (6) (7) (8) pECso values were computed for the first phase of muscarinic effects, which was characterized by the inhibitory action of carbachol on cAMP production. Proc. Natl. Acad. Sci. USA 93 (1996) I phase of carbachol action (characterized by the inhibition of cAMP synthesis) were in the range of 45-51% inhibition. In the hm2 and hm4 CHO cells that had been pretreated with pertussis toxin, the inhibitory response to carbachol was transformed to a clear-cut stimulation of cyclic [3H]AMP synthesis ( Fig. 1 b and e) .
When the same experiments were performed with alcuronium, gallamine, or strychnine instead of carbachol, similar biphasic responses of hm2 (Fig. la) and hm4 (Fig. ld) CHO cells were observed. Computed EmS, values for the inhibitory phase were in the range of 16-29% inhibition for alcuronium, 16-33% inhibition for gallamine, and 19-32% inhibition for strychnine. When the hm2 or hm4 CHO cells were pretreated with pertussis toxin, the inhibitory component of the responses to the allosteric ligands completely disappeared and the stimulatory component became prominent ( Fig. 1 b and e) The effects of allosteric ligands on rat cardiomyocytes were different from those on the hm2 and hm4 CHO cells (Fig. lc) . Thus, while carbachol decreased the rates of both the basal and the forskolin-stimulated synthesis of cyclic [3H]AMP in cardiomyocytes, all three allosteric modifiers enhanced the basal synthesis and had no effect on the synthesis stimulated by forskolin.
Changes Fig. 2c ; Em. = 3.6-fold stimulation), alcuronium and gallamine producing no change. In the rml CHO cells, the effect of allosteric agents differed between the high-expression and the low-expression cell lines. In the highexpression cell line (Fig. 2d) , the allosteric modifiers diminished the production of [3H]IPs (Ema = 10% inhibition for all three modifiers; P < 0.05), which was in contrast with their stimulatory effect in the low-expression cell line ( Fig. 2b ; Emax = 3.5-, 1.8-, and 2.7-fold stimulation for alcuronium, gallamine, and strychnine, respectively (Fig. 3b) . On the other hand, the inhibitory effect of alcuronium was preserved even in the presence of 100 nM QNB (Fig. 3b) , confirming that alcuronium did not act through the orthosteric binding site. Similarly, 100 nM QNB blocked the stimulatory effect of carbachol on the accumulation of [3H]IPs in the hml CHO cells, but it did not prevent the stimulatory effect of alcuronium (Fig. 3a) . The slight shift to the right of the dose-response curves for alcuronium, which was induced by QNB (see Fig. 3 ), is well-explained by the known negative cooperativity between the binding of alcuronium and QNB on all muscarinic receptor subtypes (17, 25, 26 and V. Dolezal, unpublished data). Alcuronium, gallamine, and strychnine are known to interact with muscarinic receptors allosterically, i.e., to bind to the receptors simultaneously with the classical agonists and antagonists and to modulate the binding of these compounds to the orthosteric binding site (8, 11, 31) . Both positive and negative changes of the affinity for antagonists have been observed under the influence of alcuronium and strychnine (11-15, 17,25, 26,31, 32) , whereas gallamine had only negative effects (7, 9-11, 16-18, 25, 33-35) . Only negative allosteric effects on the binding and action of muscarinic agonists have so far been reported for all allosteric modulators tested (6-8, 18, 31, 35-39) , although intensive work proceeds in many laboratories with the aim to discover ways how to allosterically enhance the affmity of receptors for the agonists. Because of our present results, in future studies it will be important to distinguish between the effects of allosteric modulators on the binding of agonists (i.e., on the affinity for agonists) and on the conformational changes of the receptors that are induced by agonist binding (i.e., on the productivity of receptor interaction with the G proteins).
One explanation for the observed agonist-like effects of the allosteric modulators would be to assume that endogenous acetylcholine was present in our system during incubations and that the agents investigated acted by increasing the receptors' affinity for acetylcholine. However, 100 Proc. Natl. Acad. Sci. USA 93 (1996) IX..-Proc. Natl. Acad. Sci. USA 93 (1996) 8709 phenomena on G protein-coupled receptors. It has been predicted that, depending on conditions, the same ligand may both increase and diminish the activity of its receptor (41) . In most situations encountered in the present work, the allosteric modulators alcuronium, gallamine, and strychnine shifted the equilibrium in favor of the active conformations. This is the reverse of what we (21) and others (28, (48) (49) (50) (51) (52) 
